Live Analyst Rating Changes 25550 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Asad Haider
GS

Asad Haider

Goldman Sachs
Wall Street Analyst
★★☆☆☆
#2228
on 13Foresight · ranked by our own returns
66%
Success Rate
+2.6%
Average Return
25 of 38 calls profitable · +40.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 66% of Asad Haider's ratings turned a profit when each position was held for 1 year — averaging +2.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

52 Buy 30 Hold 2 Sell
Asad's Stock Coverage 14 ratings · 2026-08-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
RPRX
Royalty Pharma
 Aug 06, 2026 BUY Strong Buy
-1.7% avg upside
15 analysts
$66.00
11.10% Upside
 +2.8% ·
LLY
Eli Lilly & Co
 Aug 06, 2026 BUY Strong Buy
-12.2% avg upside
48 analysts
$1367.00
15.50% Upside
 -0.9% ·
MRK
Merck & Company
 Aug 05, 2026 BUY Strong Buy
-4.8% avg upside
43 analysts
$140.00
2.87% Upside
 +5.9% ·
PFE
Pfizer
 Aug 04, 2026 HOLD Buy
+24.9% avg upside
45 analysts
$26.00
3.27% Downside
 +5.8% ·
JNJ
Johnson & Johnson
 Aug 03, 2026 BUY Strong Buy
-9.3% avg upside
39 analysts
$282.00
7.43% Upside
 +3.1% ·
ABBV
AbbVie
 Jul 21, 2026 HOLD Strong Buy
-3.9% avg upside
46 analysts
$244.00
2.59% Downside
 +1.1% ·
BMY
Bristol-Myers Squibb
 Jul 20, 2026 HOLD Buy
-5.5% avg upside
42 analysts
$61.00
5.65% Downside
 +9.8% ·
NAMS
NewAmsterdam Pharma Company
 May 07, 2026 HOLD Strong Buy
+76.5% avg upside
19 analysts
$38.00
41.24% Upside
 -23.0% ·
INVA
Innoviva
 May 06, 2026 SELL Buy
+36.5% avg upside
12 analysts
$18.00
14.06% Downside
 +5.9% ·
BNTX
BioNTech SE
 May 05, 2026 BUY Strong Buy
+45.7% avg upside
26 analysts
$133.00
45.15% Upside
 -2.5% ·
PCVX
Vaxcyte
 Feb 26, 2026 HOLD Strong Buy
+73.6% avg upside
15 analysts
$67.00
11.26% Upside
 +0.0% ·
XRAY
DENTSPLY SIRONA
 Dec 16, 2019 BUY Buy
+156.7% avg upside
25 analysts
$66.00
489.89% Upside
 -6.7% ·
AMGN
Amgen
 Dec 16, 2019 BUY Buy
-24.2% avg upside
57 analysts
$270.00
35.54% Downside
 -3.5% ·
ICLR
Icon
 Dec 14, 2018 BUY Strong Buy
+11.6% avg upside
26 analysts
$168.00
0.86% Downside
 +19.3% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Asad Haider — Frequently Asked Questions
How accurate are Asad Haider's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Asad's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or +40.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Asad ranked on 13Foresight?
Asad Haider is currently ranked #2228 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Asad cover?
Asad most recently has ratings on RPRX, LLY, MRK, PFE, JNJ, ABBV, BMY, NAMS, INVA, BNTX, PCVX, XRAY and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.